PUBLISHER: DelveInsight | PRODUCT CODE: 1377988
PUBLISHER: DelveInsight | PRODUCT CODE: 1377988
“"JOYCLU Drug Insight and Market Forecast - 2032" report provides comprehensive insights about JOYCLU for osteoarthritis in the six major markets. A detailed picture of the JOYCLU for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the JOYCLU for osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the JOYCLU market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. JOYCLU is the first ethical drug indicated for hip joint OA in Japan among the joint function improvement agents. JOYCLU is approved for OA treatment (knee joint and hip joint) and is expected to improve OA symptoms. Further, since JOYCLU is administered directly into the joint cavity as an injection, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is considered low. JOYCLU is a formulation in which hyaluronic acid and diclofenac (an anti-inflammatory drug) are chemically bound using Seikagaku's own proprietary technology. It is designed to release diclofenac by hydrolysis in the joint. Further, since JOYCLU is administered directly into the joint cavity as an injectable treatment, systemic exposure to diclofenac is low, and the risk of systemic adverse drug reaction is thought to be low. Ono Pharmaceutical and Seikagaku aim to contribute to the improvement of quality of life (QOL) in patients by providing a new treatment option for OA (knee joint and hip joint)
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
JOYCLU Analytical Perspective by DelveInsight
This report provides a detailed market assessment of JOYCLU for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of JOYCLU for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions